A Systems Mechanism for KRAS Mutant Allele Specific Responses to Targeted Therapy
T. McFall, J. K. Diedrich, M. Mengistu, S. L. Littlechild, K. V. Paskvan, L. Sisk-Hackworth, J. J. Moresco, A. S. Shaw, E. C. Stites
The paper investigates why KRAS G13D mutant colorectal cancers respond to anti-EGFR therapy despite general resistance, using computational models and experimental validation.
bioRxiv · Dec 10, 2018Cancer Biology